$AEON — AEON Biopharma's biosimilar development progress and defense sector advancements contrasted with persistent net losses and long-term technical downtrends.
Risk discussed: Significant net losses reported in recent years and quarters.
https://market-scanner.net/tickers/AEON.US
#ai #trading
Risk discussed: Significant net losses reported in recent years and quarters.
https://market-scanner.net/tickers/AEON.US
#ai #trading
AEON.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
October 1, 2026 at 12:35 PM
$AEON — AEON Biopharma's biosimilar development progress and defense sector advancements contrasted with persistent net losses and long-term technical downtrends.
Risk discussed: Significant net losses reported in recent years and quarters.
https://market-scanner.net/tickers/AEON.US
#ai #trading
Risk discussed: Significant net losses reported in recent years and quarters.
https://market-scanner.net/tickers/AEON.US
#ai #trading
#USSB5571: A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Status: Read twice and referred to the Committee on Finance. 2026-09-28
Sponsors:
- Republican: 3
- Democrat: 1
Status: Read twice and referred to the Committee on Finance. 2026-09-28
Sponsors:
- Republican: 3
- Democrat: 1
More Info
SB5571: A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
www.congress.gov
September 30, 2026 at 11:00 PM
#USSB5571: A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Status: Read twice and referred to the Committee on Finance. 2026-09-28
Sponsors:
- Republican: 3
- Democrat: 1
Status: Read twice and referred to the Committee on Finance. 2026-09-28
Sponsors:
- Republican: 3
- Democrat: 1
UK Could Miss Biosimilar Savings, Impacting Novartis and Peers: An industry group warned that the UK risks missing out on significant cost savings from off-patent biosimilar medicines because of pricing structures and limited uptake within the National Health… #MarketUpdates Follow Us for more
UK Could Miss Biosimilar Savings, Impacting Novartis and Peers
An industry group warned that the UK risks missing out on significant cost savings from off-patent biosimilar medicines because of pricing structures and limited uptake within the National Health Service. This could affect drugmakers like Novartis that develop and supply biosimilar products for European markets.
quantli.com
September 30, 2026 at 10:21 PM
UK Could Miss Biosimilar Savings, Impacting Novartis and Peers: An industry group warned that the UK risks missing out on significant cost savings from off-patent biosimilar medicines because of pricing structures and limited uptake within the National Health… #MarketUpdates Follow Us for more
Biosimilars cut into Humira sales and offer savings on costly medicines
https://marketbusinessnews.com/biosimilars-cut-into-humira-sales-and-offer-savings-on-costly-medicines/451606/
https://marketbusinessnews.com/biosimilars-cut-into-humira-sales-and-offer-savings-on-costly-medicines/451606/
Biosimilars cut into Humira sales and offer savings on costly medicines
AbbVie's US Humira revenue fell 47% to $425 million in the second quarter of 2026, illustrating the pressure biosimilar competition can place on a leading medicine. For healthcare systems, that competition offers a route to lower spending, although savings depend on which products reach the market and how widely they are used.
marketbusinessnews.com
September 30, 2026 at 6:56 PM
Biosimilars cut into Humira sales and offer savings on costly medicines
https://marketbusinessnews.com/biosimilars-cut-into-humira-sales-and-offer-savings-on-costly-medicines/451606/
https://marketbusinessnews.com/biosimilars-cut-into-humira-sales-and-offer-savings-on-costly-medicines/451606/
🚨 $AEON
On September 30, 2026, AEON Biopharma, Inc. issued a press release announcing receipt of the official minutes from its Biosimilar Biological Product Development Type 2b meeting with the U.S. Food and Drug Administration regarding the development pathway for ABP-450. A copy of the press re...
On September 30, 2026, AEON Biopharma, Inc. issued a press release announcing receipt of the official minutes from its Biosimilar Biological Product Development Type 2b meeting with the U.S. Food and Drug Administration regarding the development pathway for ABP-450. A copy of the press re...
SEC Filing: AEON
Click to view the official SEC document.
www.sec.gov
September 30, 2026 at 12:01 PM
🚨 $AEON
On September 30, 2026, AEON Biopharma, Inc. issued a press release announcing receipt of the official minutes from its Biosimilar Biological Product Development Type 2b meeting with the U.S. Food and Drug Administration regarding the development pathway for ABP-450. A copy of the press re...
On September 30, 2026, AEON Biopharma, Inc. issued a press release announcing receipt of the official minutes from its Biosimilar Biological Product Development Type 2b meeting with the U.S. Food and Drug Administration regarding the development pathway for ABP-450. A copy of the press re...
#AEON AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
https://www.stocktitan.net/news/AEON/aeon-biopharma-fda-type-2b-meeting-feedback-clarifies-biosimilar-ccfwa4cq3epe.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AEON/aeon-biopharma-fda-type-2b-meeting-feedback-clarifies-biosimilar-ccfwa4cq3epe.html?utm_source=stocktitan-bluesky&utm_medium=social
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 30, 2026 at 12:00 PM
#AEON AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
https://www.stocktitan.net/news/AEON/aeon-biopharma-fda-type-2b-meeting-feedback-clarifies-biosimilar-ccfwa4cq3epe.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AEON/aeon-biopharma-fda-type-2b-meeting-feedback-clarifies-biosimilar-ccfwa4cq3epe.html?utm_source=stocktitan-bluesky&utm_medium=social
[2/2] subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. 2026-09-28
Sponsors:
- Democrat: 5
- Republican: 4
Sponsors:
- Democrat: 5
- Republican: 4
More Info
HB10628: To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
www.congress.gov
September 30, 2026 at 9:40 AM
[2/2] subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. 2026-09-28
Sponsors:
- Democrat: 5
- Republican: 4
Sponsors:
- Democrat: 5
- Republican: 4
[1/2]#USHB10628: To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be
September 30, 2026 at 9:40 AM
[1/2]#USHB10628: To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be
Cetuximab-Biosimilar-Markt: Eine umfassende Analyse 2032 | WiseGuyReports www.wiseguyreports.com/de/reports/c...
Cetuximab-Biosimilar-Markt: Eine umfassende Analyse 2032
Es wird erwartet, dass die Marktgröße für Cetuximab-Biosimilars von 4,41 Milliarden US-Dollar im Jahr 2024 auf 12,5 Milliarden US-Dollar im Jahr 2032 wachsen wird. Das Cetuximab-Biosimilar Die Markt-C...
www.wiseguyreports.com
September 30, 2026 at 8:45 AM
Cetuximab-Biosimilar-Markt: Eine umfassende Analyse 2032 | WiseGuyReports www.wiseguyreports.com/de/reports/c...
We now have 3 biosimilar copies of insulin aspart (more are pending) and depending on how you count them (molecules, NDC # etc.), we have like 9 copies of glargine. And yet many patients have yet to see a benefit from increased competition. There are many reasons. blog.sstrumello.com/2026/09/why-...
September 29, 2026 at 7:42 PM
We now have 3 biosimilar copies of insulin aspart (more are pending) and depending on how you count them (molecules, NDC # etc.), we have like 9 copies of glargine. And yet many patients have yet to see a benefit from increased competition. There are many reasons. blog.sstrumello.com/2026/09/why-...
🆕 #OBSWebinars: How can countries harness the potential of biosimilar medicines?
📆 6 October 2026, 12:00-13:00 CET
🔗 tinyurl.com/OBS6October
📆 6 October 2026, 12:00-13:00 CET
🔗 tinyurl.com/OBS6October
September 29, 2026 at 7:40 PM
🆕 #OBSWebinars: How can countries harness the potential of biosimilar medicines?
📆 6 October 2026, 12:00-13:00 CET
🔗 tinyurl.com/OBS6October
📆 6 October 2026, 12:00-13:00 CET
🔗 tinyurl.com/OBS6October
Developing biosimilars of medicines that are due to come off patent could save the NHS up to £40m per year on average, a Medicines UK report has said
#ukpharmacy #biosimilar #offpatentmedicines
buff.ly/5Ewee4L
#ukpharmacy #biosimilar #offpatentmedicines
buff.ly/5Ewee4L
Supporting biosimilar development could unlock "massive demand", says trade body
Developing biosimilars of medicines that are due to come off patent could save the NHS up to £40m per year on average, a Medicines UK report has said. In its ‘UK biosimiliar void report’, published…
buff.ly
September 29, 2026 at 4:18 PM
Developing biosimilars of medicines that are due to come off patent could save the NHS up to £40m per year on average, a Medicines UK report has said
#ukpharmacy #biosimilar #offpatentmedicines
buff.ly/5Ewee4L
#ukpharmacy #biosimilar #offpatentmedicines
buff.ly/5Ewee4L
S5571
A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medi...
📢 Introduced in Senate
https://congress.gov/bill/119th-congress/senate-bill/5571
#S5571 #congress119 #senate #republican #congress #newbill
A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medi...
📢 Introduced in Senate
https://congress.gov/bill/119th-congress/senate-bill/5571
#S5571 #congress119 #senate #republican #congress #newbill
September 29, 2026 at 1:45 PM
S5571
A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medi...
📢 Introduced in Senate
https://congress.gov/bill/119th-congress/senate-bill/5571
#S5571 #congress119 #senate #republican #congress #newbill
A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medi...
📢 Introduced in Senate
https://congress.gov/bill/119th-congress/senate-bill/5571
#S5571 #congress119 #senate #republican #congress #newbill
HR10628
To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare...
📢 Introduced in House
https://congress.gov/bill/119th-congress/house-bill/10628
#HR10628 #congress119 #house #republican #congress #newbill
To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare...
📢 Introduced in House
https://congress.gov/bill/119th-congress/house-bill/10628
#HR10628 #congress119 #house #republican #congress #newbill
September 29, 2026 at 8:16 AM
HR10628
To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare...
📢 Introduced in House
https://congress.gov/bill/119th-congress/house-bill/10628
#HR10628 #congress119 #house #republican #congress #newbill
To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare...
📢 Introduced in House
https://congress.gov/bill/119th-congress/house-bill/10628
#HR10628 #congress119 #house #republican #congress #newbill
🚨 BREAKING: #$TEVA just won FDA approval for DEGEVMA, a biosimilar to Xgeva for treating bone complications in advanced cancer patients. 5 analysts have rated it in the past year, all at buy, with targets from $42 to $50.
September 28, 2026 at 8:17 PM
🚨 BREAKING: #$TEVA just won FDA approval for DEGEVMA, a biosimilar to Xgeva for treating bone complications in advanced cancer patients. 5 analysts have rated it in the past year, all at buy, with targets from $42 to $50.
Erythropoietin and Biosimilar Market Forecasting Growth 2035 | WiseGuyReports www.wiseguyreports.com/reports/epog...
Erythropoietin and Biosimilar Market Forecasting Growth 2035
The Erythropoietin and Biosimilar Market is expected to grow from 34.8 USD Billion in 2025 to 45.2 USD Billion by 2035. The Erythropoietin and Biosimilar Market CAGR (growth rate) is expected to be ar...
www.wiseguyreports.com
September 28, 2026 at 5:24 AM
Erythropoietin and Biosimilar Market Forecasting Growth 2035 | WiseGuyReports www.wiseguyreports.com/reports/epog...
NCCN guidelines identify the molecule not an explicit brand or generic, so yes the option can presented particularly when a generic/biosimilar is first launched
September 28, 2026 at 12:58 AM
NCCN guidelines identify the molecule not an explicit brand or generic, so yes the option can presented particularly when a generic/biosimilar is first launched
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive www.kff.org/health-costs...
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive | KFF
Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those...
www.kff.org
September 27, 2026 at 1:36 AM
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive www.kff.org/health-costs...
$300B+ in drug revenue is nearing Loss of Exclusivity.
PatentCliffClock tracks major pharma patent expirations in real time.
LucidWargames helps teams rehearse their LOE response before it hits.
Explore: http://dlvr.it/TVfZ71
Simulate: http://dlvr.it/TVfZ75
PatentCliffClock tracks major pharma patent expirations in real time.
LucidWargames helps teams rehearse their LOE response before it hits.
Explore: http://dlvr.it/TVfZ71
Simulate: http://dlvr.it/TVfZ75
Patent Cliff Doomsday Clock — Live Countdown to Drug Patent Expiry
Real-time countdowns for every major pharmaceutical patent expiration. Track when blockbuster drugs lose exclusivity and face generic or biosimilar competition.
dlvr.it
September 26, 2026 at 9:19 AM
$300B+ in drug revenue is nearing Loss of Exclusivity.
PatentCliffClock tracks major pharma patent expirations in real time.
LucidWargames helps teams rehearse their LOE response before it hits.
Explore: http://dlvr.it/TVfZ71
Simulate: http://dlvr.it/TVfZ75
PatentCliffClock tracks major pharma patent expirations in real time.
LucidWargames helps teams rehearse their LOE response before it hits.
Explore: http://dlvr.it/TVfZ71
Simulate: http://dlvr.it/TVfZ75
Project Insulin Partners with BioEthica to Advance FDA Regulatory Strategy for Biosimilar Insulin Glargine projectinsulin.org/pressrelease...
Press Releases | Project Insulin
Press Release Project Insulin Partners with BioEthica to Advance FDA Regulatory Strategy for Biosimilar Insulin Glargine Press Release | September 2026 Pres ...
projectinsulin.org
September 25, 2026 at 2:30 PM
Project Insulin Partners with BioEthica to Advance FDA Regulatory Strategy for Biosimilar Insulin Glargine projectinsulin.org/pressrelease...
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - A landscape of sequence variants in 51 commercial antibody therapeutics.
doi.org/10.1093/abt/...
#antibodydiscovery #antibodytherapeutics #biologics #sequencevariant #biosimilar #massspectrometry
doi.org/10.1093/abt/...
#antibodydiscovery #antibodytherapeutics #biologics #sequencevariant #biosimilar #massspectrometry
September 25, 2026 at 1:51 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - A landscape of sequence variants in 51 commercial antibody therapeutics.
doi.org/10.1093/abt/...
#antibodydiscovery #antibodytherapeutics #biologics #sequencevariant #biosimilar #massspectrometry
doi.org/10.1093/abt/...
#antibodydiscovery #antibodytherapeutics #biologics #sequencevariant #biosimilar #massspectrometry
Bevacizumab Monoclonal Antibody Biosimilar Market 2035 | WiseGuyReports www.wiseguyreports.com/reports/beva...
www.wiseguyreports.com
September 25, 2026 at 9:27 AM
Bevacizumab Monoclonal Antibody Biosimilar Market 2035 | WiseGuyReports www.wiseguyreports.com/reports/beva...
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive
www.kff.org/health-costs...
www.kff.org/health-costs...
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive | KFF
Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those...
www.kff.org
September 25, 2026 at 9:17 AM
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive
www.kff.org/health-costs...
www.kff.org/health-costs...
Cetuximab-Biosimilar-Markt: Eine umfassende Analyse 2032 | WiseGuyReports www.wiseguyreports.com/de/reports/c...
Cetuximab-Biosimilar-Markt: Eine umfassende Analyse 2032
Es wird erwartet, dass die Marktgröße für Cetuximab-Biosimilars von 4,41 Milliarden US-Dollar im Jahr 2024 auf 12,5 Milliarden US-Dollar im Jahr 2032 wachsen wird. Das Cetuximab-Biosimilar Die Markt-C...
www.wiseguyreports.com
September 25, 2026 at 7:51 AM
Cetuximab-Biosimilar-Markt: Eine umfassende Analyse 2032 | WiseGuyReports www.wiseguyreports.com/de/reports/c...